NCT02855125View on ClinicalTrials.gov

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

PHASE2CompletedINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

August 29, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

November 30, 2017

Conditions

Advanced or Metastatic Non-small Cell Lung Cancer

Interventions

DRUG

TAS-114

TAS-114 was a modulator of 5-fluorouracil (5-FU).

DRUG

S-1

S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.

Trial Locations (30)

Unknown

Loma Linda

Gainesville

Cleveland

Portland

Dallas

Seattle

Caen

Lille

Marseille

Paris

Pierre-Bénite

Villejuif

Catania

Milan

Palermo

Ravenna

Kashiwa

Chuo-Ku

Sunto-Gun

Katowice

Lodz

Lublin

Warsaw

Badalona

Barcelona

Madrid

589-8511

Sayama

362-0806

Adachi

135-8550

Koto-Ku

641-8509

Wakayama

All Listed Sponsors

lead

Taiho Oncology, Inc.

INDUSTRY

NCT02855125 - A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1 | Biotech Hunter | Biotech Hunter